Endoscopy 2008; 40(10): 823-827
DOI: 10.1055/s-2008-1077568
DDW highlights

© Georg Thieme Verlag KG Stuttgart · New York

Reflux disease and Barrett’s esophagus

J.  A.  Abrams1 , 2 , C.  J.  Lightdale1 , 2
  • 1Division of Digestive and Liver Disease, Columbia University Medical Center, New York, New York, USA
  • 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
Further Information

Publication History

Publication Date:
30 September 2008 (online)

Introduction

Despite the high prevalence of gastroesophageal reflux disease (GERD) and, to a lesser degree, Barrett’s esophagus in the Western world, there are still many unknowns with regard to the epidemiology, natural history, and appropriate treatments for these conditions. There is a significant amount of ongoing research into endoscopic treatment modalities in an attempt to reduce the need for medical therapy for GERD. Meanwhile, the underlying biology of Barrett’s carcinogenesis is incompletely understood, as is the ideal treatment for Barrett’s esophagus and advanced neoplasia.

References

  • 1 Pace F, Bollani S, Molteni P. et al . Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on.  Dig Liver Dis. 2004;  36 111-115
  • 2 Locke 3rd G R. Natural history of nonerosive reflux disease. Is all gastroesophageal reflux disease the same? What is the evidence?.  Gastroenterol Clin North Am. 2002;  31 S59-S66
  • 3 Ronkainen J, Aro P, Storskrubb T. et al . Natural history of NERD in the general population, the Kalixanda study.  Gastroenterology. 2008;  134 A74
  • 4 El-Serag H. Role of obesity in GORD-related disorders.  Gut. 2008;  57 281-284
  • 5 Ruhl C E, Everhart J E. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey.  Ann Epidemiol. 1999;  9 424-435
  • 6 El-Serag H B, Petersen N J, Carter J. et al . Gastroesophageal reflux among different racial groups in the United States.  Gastroenterology. 2004;  126 1692-1699
  • 7 Singson Z, Vega K, Jamal M M. Trends in the endoscopic spectrum of GERD among a large cohort of patients.  Gastroenterology. 2008;  134 A39
  • 8 Jazrawi S, Walsh T N, Byrne P J. et al . Cholecystectomy and oesophageal reflux: a prospective evaluation.  Br J Surg. 1993;  80 50-53
  • 9 McNamara D A, O’Donohoe M K, Horgan P G. et al . Symptoms of oesophageal reflux are more common following laparoscopic cholecystectomy than in a control population.  Ir J Med Sci. 1998;  167 11-13
  • 10 Maddern G J, Baxter P S. The effect of laparoscopic cholecystectomy on gastroduodenal reflux.  Aust N Z J Surg. 1997;  67 703-705
  • 11 Manifold D K, Anggiansah A, Owen W J. Effect of cholecystectomy on gastroesophageal and duodenogastric reflux.  Am J Gastroenterol. 2000;  95 2746-2750
  • 12 Lin O, Kozarek R A. The association between cholecystectomy and gastroesophageal reflux symptoms.  Gastrointest Endosc. 2008;  67 AB85
  • 13 Aanen M C, Weusten B L, Numans M E. et al . Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care.  Aliment Pharmacol Ther. 2006;  24 1377-1384
  • 14 des Varannes S B, Sacher-Huvelin S, Vavasseur F. et al . Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.  World J Gastroenterol. 2006;  12 2569-2573
  • 15 Numans M E, Lau J, de Wit N J. et al . Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.  Ann Intern Med. 2004;  140 518-527
  • 16 Bytzer P, Jones R, Vakil N. et al . Evaluation of the proton pump inhibitor (PPI) test for the diagnosis of GERD: Results from the Diamond study.  Gastroenterology. 2008;  134 A100
  • 17 Morana E, Guida L, Cavallaro L G. et al . Gastrin-17 (G-17): a serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD).  Gastroenterology. 2008;  134 A101
  • 18 Monkemuller K, Neumann H, Nocon M. et al . Serum gastrin and pepsinogens do not correlate with the different grades of severity of GERD: a matched case-control study.  Aliment Pharmacol Ther. 2008;  in press
  • 19 Demaria E J, Jamal M K. Surgical options for obesity.  Gastroenterol Clin North Am. 2005;  34 127-142
  • 20 Pohl D, Mueller M K, Wildi S. et al . Gastroesophageal reflux and esophageal peristalsis before and after gastric bypass surgery – an interim analysis of combined impedance-pH and high resolution manometry data.  Gastroenterology. 2008;  134 A13
  • 21 Kubo A, Corley D A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.  Cancer Epidemiol Biomarkers Prev. 2006;  15 872-878
  • 22 Vakil N. Review article: the role of surgery in gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2007;  25 1365-1372
  • 23 Lundell L. Therapy of gastroesophageal reflux: evidence-based approach to antireflux surgery.  Dig Dis. 2007;  25 188-196
  • 24 Hatlebakk J G, Lundell L R, Galmiche J P. et al . Initial control of acid reflux after laparoscopic anti-reflux surgery (LARS) compared to chronic use of esomeprazole (ESO) 20 – 40 mg daily.  Gastroenterology. 2008;  134 A125
  • 25 Pleskow D, Rothstein R, Kozarek R. et al . Endoscopic full-thickness plication for the treatment of GERD: five-year long-term multicenter results.  Surg Endosc. 2008;  22 326-332
  • 26 Pleskow D, Rothstein R, Kozarek R. et al . Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results.  Surg Endosc. 2007;  21 439-444
  • 27 Corsetti M, Passaretti S M, Di Pietro S. et al . Effect of the EsophyX device for endoluminal fundoplication on symptoms, esophageal manometry and pH-impedence of patients with gastro-esophageal reflux.  Gastroenterology. 2008;  134 A13
  • 28 Wong A, Fitzgerald R C. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma.  Clin Gastroenterol Hepatol. 2005;  3 1-10
  • 29 de Jonge P J, van Blankenstein M, Looman C W. et al . Trends in the incidence of Barrett’s esophagus in the Netherlands 1991 – 2006.  Gastroenterology. 2008;  134 A39
  • 30 Conio M, Blanchi S, Lapertosa G. et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.  Am J Gastroenterol. 2003;  98 1931-1939
  • 31 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
  • 32 Sikkema M, Kerkhof M, Steyerberg E W. et al . Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients.  Gastrointest Endosc. 2008;  67 AB75
  • 33 Wang K K, Sampliner R E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2008;  103 788-797
  • 34 McCallum A L, Macpherson M, Jenkins J T. et al . Autofluorescence assessment in the surveillance of Barrett’s oesophagus: a randomised trial comparing standard 4 quadrant biopsy and AF directed biopsy.  Gastroenterology. 2008;  134 A63
  • 35 Wolfsen H C, Crook J E, Krishna M. et al . Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus.  Gastroenterology. 2008;  135 24-31
  • 36 Dunbar K B, Montgomery E A, Okolo P. et al . Confocal laser endomicroscopy in Barrett’s esophagus and associated neoplasia: a prospective randomized controlled crossover trial.  Gastrointest Endosc. 2008;  67 AB97
  • 37 Reid B J, Blount P L, Rabinovitch P S. Biomarkers in Barrett’s esophagus.  Gastrointest Endosc Clin N Am. 2003;  13 369-397
  • 38 Sikkema M, Kerkhof M, Steyerberg E W. et al . Flow cytometry in Barrett esophagus (Cybar Study): a prospective cohort study.  Gastroenterology. 2008;  134 A110
  • 39 Spechler S J. Barrett’s esophagus: a molecular perspective.  Curr Gastroenterol Rep. 2005;  7 177-181
  • 40 Berman D M, Karhadkar S S, Maitra A. et al . Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.  Nature. 2003;  425 846-851
  • 41 Oh D S, DeMeester S R, Mori R. et al . Sonic Hedgehog gene expression in Barrett’s esophagus and esophageal adencoarcinoma.  Gastroenterology. 2008;  134 A150
  • 42 Shaheen N J, Sharma P, Overholt B F. et al . A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial.  Gastroenterology. 2008;  134 A37
  • 43 Reed M F, Tolis Jr G, Edil B H. et al . Surgical treatment of esophageal high-grade dysplasia.  Ann Thorac Surg. 2005;  79 1110-1115; discussion 1110 – 1115
  • 44 Konda V J, Chennat J S, Ross A S. et al . Low rate of invasive cancer in patients undergoing mucosectomy for Barrett’s esophagus (BE) and high grade dysplasia (HGD) or intramucosal carcinoma (IMC).  Gastrointest Endosc. 2008;  67 AB76
  • 45 Conio M, Ponchon T, Blanchi S. et al . Endoscopic mucosal resection.  Am J Gastroenterol. 2006;  101 653-663
  • 46 Manner H, May A, Pech O. et al . Are patients with ”low risk“ submucosal invasion of early Barrett’s carcinoma eligible for curative endoscopic therapy? Outcomes of endoscopic therapy and surgery in 80 patients with suspected or definite diagnosis of submucosal Barrett’s cancer.  Gastrointest Endosc. 2008;  67 AB75

C. J. LightdaleMD 

Columbia University Medical Center

180 Ft. Washington Ave.
Harkness Pavilion 7-712
New York
NY 10032
USA

Fax: +1-212-3059913

Email: cjl18@columbia.edu

    >